Literature DB >> 29388273

Secretion of wild-type factor IX upon readthrough over F9 pre-peptide nonsense mutations causing hemophilia B.

Mattia Ferrarese1, Maria Francesca Testa1, Dario Balestra1, Francesco Bernardi1, Mirko Pinotti1, Alessio Branchini1.   

Abstract

Pre-peptide regions of secreted proteins display wide sequence variability, even among highly homologous proteins such as coagulation factors, and are intracellularly removed, thus potentially favoring secretion of wild-type proteins upon suppression of nonsense mutations (translational readthrough). As models we selected F9 nonsense mutations with readthrough-favorable features affecting the pre-peptide and pro-peptide regions of coagulation factor IX (FIX), which cause hemophilia B (HB). Only the p.Gly21Ter (c.61G > T) in the variable pre-peptide hydrophobic core significantly responded (secretion, 4.1 ± 0.5% of wild-type; coagulant activity, 4.0 ± 0.3%) to the readthrough-inducer geneticin. Strikingly, for the p.Gly21Ter mutation, the resulting specific coagulant activity (0.96 ± 0.11) was compatible with normal function, thus suggesting secretion of FIX with wild-type features upon readthrough and removal of pre-peptide. Expression of the predicted readthrough-deriving missense variants (Gly21Trp/Cys/Arg) revealed a preserved specific activity (ranging from 0.84 to 0.98), thus supporting our observation. Conversely, rescue of the p.Cys28Ter (c.84T > A) and p.Lys45Ter (c.133A > T) was prevented by constraints of adjacent cleavage sites, a finding consistent with the association of most missense mutations affecting these regions with severe or moderate HB. Overall, our data indicate that suppression of nonsense mutations in the pre-peptide core preserves mature protein features, thus making this class of mutations preferred candidates for therapeutic readthrough.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  coagulation factor IX; hemophilia B; nonsense mutations; pre-peptide; readthrough

Mesh:

Substances:

Year:  2018        PMID: 29388273     DOI: 10.1002/humu.23404

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  10 in total

1.  Aminoglycoside drugs induce efficient read-through of CDKL5 nonsense mutations, slightly restoring its kinase activity.

Authors:  Maria Fazzari; Angelisa Frasca; Francesco Bifari; Nicoletta Landsberger
Journal:  RNA Biol       Date:  2019-06-23       Impact factor: 4.652

2.  Translational readthrough of GLA nonsense mutations suggests dominant-negative effects exerted by the interaction of wild-type and missense variants.

Authors:  Silvia Lombardi; Mattia Ferrarese; Saverio Marchi; Paolo Pinton; Mirko Pinotti; Francesco Bernardi; Alessio Branchini
Journal:  RNA Biol       Date:  2019-10-15       Impact factor: 4.652

3.  Identification of candidate nonsense mutations of FVIII for ribosomal readthrough therapy.

Authors:  Zhigang Liu; Yuan Zhang; Min Zhu; Bin Zhang
Journal:  Haematologica       Date:  2019-04-19       Impact factor: 9.941

4.  F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes.

Authors:  Alessio Branchini; Massimo Morfini; Barbara Lunghi; Donata Belvini; Paolo Radossi; Loredana Bury; Maria Luisa Serino; Paola Giordano; Dorina Cultrera; Angelo Claudio Molinari; Mariasanta Napolitano; Elisabetta Bigagli; Giancarlo Castaman; Mirko Pinotti; Francesco Bernardi
Journal:  J Thromb Haemost       Date:  2021-10-24       Impact factor: 16.036

5.  An Altered Splicing Registry Explains the Differential ExSpeU1-Mediated Rescue of Splicing Mutations Causing Haemophilia A.

Authors:  Dario Balestra; Iva Maestri; Alessio Branchini; Mattia Ferrarese; Francesco Bernardi; Mirko Pinotti
Journal:  Front Genet       Date:  2019-10-10       Impact factor: 4.599

6.  Next-generation sequencing and recombinant expression characterized aberrant splicing mechanisms and provided correction strategies in factor VII deficiency.

Authors:  Paolo Ferraresi; Dario Balestra; Caroline Guittard; Delphine Buthiau; Brigitte Pan-Petesh; Iva Maestri; Roula Farah; Mirko Pinotti; Muriel Giansily-Blaizot
Journal:  Haematologica       Date:  2019-07-04       Impact factor: 9.941

7.  An Exon-Specific Small Nuclear U1 RNA (ExSpeU1) Improves Hepatic OTC Expression in a Splicing-Defective spf/ash Mouse Model of Ornithine Transcarbamylase Deficiency.

Authors:  Dario Balestra; Mattia Ferrarese; Silvia Lombardi; Nicole Ziliotto; Alessio Branchini; Naomi Petersen; Piter Bosma; Mirko Pinotti; Stan F J van de Graaf
Journal:  Int J Mol Sci       Date:  2020-11-19       Impact factor: 5.923

Review 8.  Molecular Insights into Determinants of Translational Readthrough and Implications for Nonsense Suppression Approaches.

Authors:  Silvia Lombardi; Maria Francesca Testa; Mirko Pinotti; Alessio Branchini
Journal:  Int J Mol Sci       Date:  2020-12-11       Impact factor: 5.923

9.  A Compensatory U1snRNA Partially Rescues FAH Splicing and Protein Expression in a Splicing-Defective Mouse Model of Tyrosinemia Type I.

Authors:  Dario Balestra; Daniela Scalet; Mattia Ferrarese; Silvia Lombardi; Nicole Ziliotto; Chrystal C Croes; Naomi Petersen; Piter Bosma; Federico Riccardi; Franco Pagani; Mirko Pinotti; Stan F J van de Graaf
Journal:  Int J Mol Sci       Date:  2020-03-20       Impact factor: 5.923

10.  Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity.

Authors:  Silvia Lombardi; Kristin H Aaen; Jeannette Nilsen; Mattia Ferrarese; Torleif T Gjølberg; Francesco Bernardi; Mirko Pinotti; Jan T Andersen; Alessio Branchini
Journal:  Br J Haematol       Date:  2021-06-09       Impact factor: 6.998

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.